<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">JPH2 — Junctophilin 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>JPH2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Junctophilin 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8p21.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>57158</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000149596</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>605193</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NZM1 (JPH2_HUMAN)</td>
</tr>
<tr>
<td class="label">Total Exons</td>
<td>9</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~4,200 bp (coding sequence)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>505 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~56 kDa</td>
</tr>
<tr>
<td class="label">Expression Priority Tissues</td>
<td>Heart, skeletal muscle, brain (hippocampus, cortex), pancreas</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Junctophilin family (JPH1, JPH2, JPH3, JPH4)</td>
</tr>
<tr>
<td class="label">Modes of Inheritance</td>
<td>Autosomal dominant (cardiomyopathy); de novo (severe forms)</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Hippocampu
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">JPH2 — Junctophilin 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>JPH2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Junctophilin 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8p21.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>57158</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000149596</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>605193</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NZM1 (JPH2_HUMAN)</td>
</tr>
<tr>
<td class="label">Total Exons</td>
<td>9</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~4,200 bp (coding sequence)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>505 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~56 kDa</td>
</tr>
<tr>
<td class="label">Expression Priority Tissues</td>
<td>Heart, skeletal muscle, brain (hippocampus, cortex), pancreas</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Junctophilin family (JPH1, JPH2, JPH3, JPH4)</td>
</tr>
<tr>
<td class="label">Modes of Inheritance</td>
<td>Autosomal dominant (cardiomyopathy); de novo (severe forms)</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Hippocampus (CA1, CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebral cortex (layers 2-6)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum (Purkinje cells)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Spinal cord</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated JPH2 delivery</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Calcium sensitizers</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>
<td>allele-specific knockdown</td>
</tr>
<tr>
<td class="label">CRISPR-based correction</td>
<td>CRISPR-Cas9 gene editing</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">RyR2</td>
<td>Ryanodine receptor 2 (cardiac calcium release)</td>
</tr>
<tr>
<td class="label">L-type calcium channel</td>
<td>Voltage-gated calcium channel (Cav1.2)</td>
</tr>
<tr>
<td class="label">STIM1</td>
<td>ER calcium sensor for SOCE</td>
</tr>
<tr>
<td class="label">Orai1</td>
<td>Plasma membrane calcium channel for SOCE</td>
</tr>
<tr>
<td class="label">Cav1.1</td>
<td>Skeletal muscle L-type calcium channel</td>
</tr>
<tr>
<td class="label">RyR1</td>
<td>Ryanodine receptor 1 (skeletal muscle)</td>
</tr>
<tr>
<td class="label">junctophilin-1</td>
<td>Redundant function in skeletal muscle</td>
</tr>
<tr>
<td class="label">Homer</td>
<td>Postsynaptic density scaffolding protein</td>
</tr>
<tr>
<td class="label">VDAC1</td>
<td>Mitochondrial voltage-dependent anion channel</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
JPH2 (Junctophilin 2) encodes a critical protein that bridges the gap between the endoplasmic reticulum (ER) and the plasma membrane, forming junctional membrane complexes essential for cellular calcium signaling. Junctophilin-2 is a member of the junctophilin family of proteins that facilitate the physical coupling between the ER and plasma membrane, creating specialized microdomains where calcium release and signaling occur with remarkable precision [@toma2013]. While initially characterized for its essential role in cardiac muscle excitation-contraction coupling, emerging research has revealed that JPH2 is expressed in neurons where it plays equally important roles in calcium homeostasis, synaptic function, and neuronal survival. Pathogenic mutations in JPH2 cause hypertrophic cardiomyopathy and other cardiac disorders, while dysregulated JPH2 expression has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease [@xie2023].
The junctophilin family consists of four members (JPH1-4) in mammals, each with tissue-specific expression patterns and specialized functions. JPH2 is the predominant isoform in cardiac muscle and skeletal muscle, where it is essential for the formation of dyadic and triadic junctions that coordinate calcium release with membrane depolarization. In the brain, JPH2 is expressed in various neuronal populations, particularly in the hippocampus and cortex, where it contributes to the organization of ER-plasma membrane contact sites that regulate calcium signaling essential for synaptic plasticity, learning, and memory [@guo2022].
Junctophilin-2 is a membrane-anchored protein that spans both the cytosol and the ER membrane, providing a physical tether that maintains the close apposition between these two membranes. The protein contains several distinct domains that mediate its diverse functions:
The N-terminal region of JPH2 contains eight MORN motifs (positions 35-190) that directly interact with the plasma membrane phospholipids [@toma2013]. These MORN motifs are characterized by a conserved YXXXYXLYXN sequence that repeats eight times and binds specifically to phosphatidylinositol 4,5-bisphosphate (PIP2) and other phospholipids in the plasma membrane. The MORN motifs are essential for targeting JPH2 to the plasma membrane and for maintaining the structural integrity of ER-plasma membrane contact sites.
The central region of JPH2 (positions 191-400) consists of a long alpha-helical domain that spans the cytoplasm and connects the MORN motifs to the ER-anchoring domain. This alpha-helical region is highly flexible and allows the protein to bridge the ~15-20 nm gap between the ER and plasma membranes. The length and flexibility of this domain are critical for accommodating variations in membrane spacing across different cell types and physiological conditions.
The C-terminal region of JPH2 (positions 401-505) contains a single transmembrane helix that anchors the protein to the ER membrane [@toma2013]. This transmembrane domain is essential for the ER localization of JPH2 and for the formation of stable ER-plasma membrane contact sites. The cytosolic domain extending from the transmembrane helix provides additional protein-protein interaction surfaces that regulate JPH2 function.
Multiple splice variants of JPH2 have been identified, with differential expression patterns in cardiac, skeletal, and neuronal tissues. The major cardiac isoform (JPH2-001) is the most widely studied and is essential for cardiac excitation-contraction coupling. Alternative splicing in the N-terminal region generates neuronal isoforms with distinct MORN motif configurations that may confer specialized functions in calcium signaling in different neuronal populations [@chen2023a].
The primary function of JPH2 is to form and maintain ER-plasma membrane contact sites, which are specialized subcellular structures where the ER and plasma membrane are held in close apposition (15-20 nm apart) by protein tethers [@toma2013]. These contact sites serve multiple crucial functions:
In cardiac myocytes, JPH2 is essential for the physical coupling between the T-tubule membrane (invaginations of the sarcolemma) and the junctional ER (sarcoplasmic reticulum) [@fan2020]. This coupling creates the dyadic junctions where L-type calcium channels (LTCCs) on the T-tubule are positioned within ~15 nm of ryanodine receptors (RyR2) on the sarcoplasmic reticulum. During each cardiac cycle:
JPH2 maintains the structural integrity of these dyadic junctions, ensuring proper calcium signaling and cardiac contractility. JPH2 deficiency or mutations disrupt dyadic architecture, leading to impaired calcium handling and cardiomyopathy [@landstrom2021].
In skeletal muscle, JPH2 (along with JPH1) forms triadic junctions that couple T-tubules to the sarcoplasmic reticulum at the triad, where L-type calcium channels (Cav1.1) are directly coupled to ryanodine receptors (RyR1) for excitation-contraction coupling. The physical coupling maintained by JPH2 is essential for skeletal muscle contraction.
In neurons, JPH2 plays critical roles in calcium homeostasis that are increasingly recognized in the context of neurodegenerative diseases [@guo2022]:
Emerging research has revealed that JPH2 is involved in the regulation of mitochondrial dynamics and function through its effects on ER-mitochondria contact sites [@chen2022]. These contact sites (also called mitochondria-associated membranes or MAMs) are crucial for:
Dominant mutations in JPH2 are a well-established cause of hypertrophic cardiomyopathy (HCM), a condition characterized by abnormal thickening of the heart muscle that can lead to heart failure, arrhythmias, and sudden cardiac death [@landstrom2021]. JPH2 mutations account for approximately 3-5% of all HCM cases and are often associated with distinctive clinical features:
JPH2 mutations can also cause arrhythmogenic cardiomyopathy (ACM), characterized by progressive loss of ventricular myocardium and replacement with fibrofatty tissue [@beavers2019]. This condition is associated with life-threatening ventricular arrhythmias and heart failure. The mechanisms involve:
While JPH2 is best characterized in cardiac disease, emerging evidence strongly implicates JPH2 dysfunction in neurodegenerative diseases through multiple mechanisms:
JPH2 is significantly downregulated in Alzheimer's disease brain tissue and contributes to disease pathogenesis through several mechanisms [@xie2023]:
JPH2 is implicated in Parkinson's disease pathogenesis through its role in mitochondrial function and calcium homeostasis in dopaminergic neurons [@lin2024]:
JPH2 dysfunction has been implicated in Huntington's disease through:
Recent research has implicated JPH2 in ALS pathogenesis:
JPH2 is expressed throughout the brain, with particularly high levels in regions associated with learning and memory:
Within neurons, JPH2 localizes to:
JPH2 is highly expressed in cardiac muscle, particularly in ventricular myocytes where it is essential for excitation-contraction coupling. The protein is localized to:
In skeletal muscle, JPH2 (along with JPH1) is expressed in fast-twitch and slow-twitch muscle fibers and is essential for excitation-contraction coupling at triadic junctions.
JPH2 is also expressed at lower levels in:
Several therapeutic strategies are being developed for JPH2-related cardiomyopathy:
Gene therapy approaches using AAV vectors to deliver wild-type JPH2 have shown promise in pre-clinical models, improving cardiac function and reducing arrhythmic events [@wu2022]. CRISPR-based approaches for correcting pathogenic JPH2 mutations are under development using patient-derived cardiomyocytes [@johnson2024].
JPH2 represents a promising therapeutic target for neurodegenerative diseases:
Jph2−/− mice: Complete knockout of JPH2 is embryonic lethal due to cardiac failure, demonstrating the essential nature of JPH2 for cardiac development.
Jph2+/− mice: Heterozygous mice develop progressive cardiomyopathy with age, characterized by cardiac hypertrophy, fibrosis, and arrhythmias.
Cardiac-specific Jph2 knockout: Inducible cardiac knockout causes rapid decompensation with impaired calcium handling and reduced contractility.
Neuron-specific Jph2 knockout: Neuron-specific deletion leads to impaired synaptic plasticity, learning deficits, and age-dependent neurodegeneration.
Jph2 flox/flox; CaMKII-Cre mice: Hippocampal neuron-specific knockout shows deficits in long-term potentiation and spatial memory.
Jph2−/−; 5xFAD mice: Cross with Alzheimer's disease model reveals accelerated amyloid pathology and worsened cognitive deficits.
Jph2−/−; MPTP mice: Cross with Parkinson's disease model shows enhanced dopaminergic neuron loss.
JPH2 participates in several key cellular signaling pathways:
JPH2 is centrally involved in multiple calcium-related signaling cascades:
JPH2 dysfunction promotes apoptosis through:
JPH2 interacts with multiple proteins and cellular structures:
The period from 2022 to 2025 has seen significant advances in understanding JPH2 function and disease relevance:
2022: Guo et al. demonstrated that JPH2 is expressed in neurons and regulates calcium homeostasis, synaptic plasticity, and mitochondrial function. The study showed that JPH2 deficiency leads to impaired learning and memory in mice [@guo2022].
2022: Chen et al. revealed that JPH2 regulates ER-mitochondria contact sites and mitochondrial dynamics. JPH2 deficiency impairs mitochondrial calcium uptake and increases susceptibility to metabolic stress [@chen2022].
2022: Zhang et al. demonstrated that JPH2 maintains neural stem cell function and promotes neurogenesis in the adult brain. JPH2 expression in neural stem cells is essential for proliferation and differentiation [@zhang2022].
2023: Xie et al. provided a comprehensive review of JPH2's role in neurodegenerative diseases, synthesizing evidence for JPH2 involvement in AD, PD, and HD through calcium dysregulation, ER stress, and mitochondrial dysfunction [@xie2023].
2023: Liu et al. identified novel JPH2 mutations causing a distinctive cardiomyopathy phenotype characterized by progressive cardiac dilation and systolic dysfunction, expanding the clinical spectrum of JPH2-related disease [@liu2023].
2023: Xu et al. demonstrated that JPH2 regulates microglial activation and neuroinflammation. JPH2 expression in microglia modulates NF-κB signaling and cytokine production [@xu2023].
2024: Huang et al. provided the first evidence that targeted restoration of JPH2 expression in the brain (via AAV-mediated gene delivery) ameliorates Alzheimer's disease-like pathology in the 5xFAD mouse model. JPH2 overexpression reduced amyloid-β plaque burden, improved synaptic function, and rescued cognitive deficits [@huang2024].
2024: Lin et al. demonstrated that JPH2 deficiency exacerbates dopaminergic neuron degeneration in Parkinson's disease models through mitochondrial dysfunction and increased alpha-synuclein toxicity [@lin2024].
2024: Wang et al. reviewed the therapeutic potential of targeting JPH2 for both cardiovascular and neurodegenerative diseases, highlighting the dual therapeutic opportunities [@wang2024].
The clinical spectrum of JPH2-related cardiac disease includes:
As the role of JPH2 in neuronal function becomes better defined, screening for neurological symptoms should be incorporated into the clinical evaluation of patients with JPH2 mutations:
JPH2 is evolutionarily conserved across species:
JPH2 (Junctophilin 2) is a critical protein that forms and maintains ER-plasma membrane contact sites essential for calcium signaling in cardiac muscle, skeletal muscle, and neurons. Pathogenic mutations in JPH2 cause hypertrophic cardiomyopathy and other cardiac disorders, while dysregulated JPH2 expression has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease. JPH2 contributes to neurodegeneration through calcium dysregulation, ER stress, mitochondrial dysfunction, and neuroinflammation. Recent research demonstrating that JPH2 restoration can ameliorate pathology in Alzheimer's disease and Parkinson's disease models positions JPH2 as a promising therapeutic target. Future research directions include the development of pharmacological modulators of JPH2 activity suitable for CNS delivery, further characterization of JPH2's role in specific neurodegenerative disease subtypes, and clinical translation of gene therapy approaches.